BioWorld

Dec. 1, 2005

InSite's Pink Eye Treatment Proves Positive In Phase III

PIramed In $230M Preclinical Cancer Deal With Genentech

VC Syndication Key For Young European Biotechnology Firms

Other News To Note

BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal

The holiday season is coming early to BioCryst Pharmaceuticals Inc., which could earn more than half a billion dollars per terms of a just-announced licensing deal with F. Hoffmann-La Roche Ltd. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...